`Filed: April 20, 2020
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________________
`
`MODERNA THERAPEUTICS, INC.,
`Petitioner,
`
`v.
`
`ARBUTUS BIOPHARMA CORPORATION
`Patent Owner.
`
`—————————————————
`Case IPR2019-00554
`Patent No. 8,058,069
`_____________________________
`
`PATENT OWNER’S NOTICE OF OBJECTION TO
`DEMONSTRATIVE EXHIBITS
`
`
`
`
`
`
`
`I.
`
`INTRODUCTION
`
`Pursuant to the Board’s trial hearing order (Paper 32, 4), Arbutus Biopharma
`
`Corporation (“Patent Owner”) submits the following objections to Moderna
`
`Therapeutics, Inc. (“Petitioner”)’s demonstrative slides, and any reference to or
`
`reliance on the foregoing by Petitioner. The demonstrative slides are objected to
`
`under FRE106, 401, 403, and 705. Further non-limiting discussion is provided
`
`below and is meant to illustrate the objectionable content.
`
`II. OBJECTIONS
`
`1.
`Slides 5 and 29
`Slides 5 and 29 are improper as irrelevant to the obviousness inquiry – the
`
`’910 publication is not a grounds reference. FRE106, 401, 403. Additionally, the
`
`documents are incomplete and more prejudicial than probative. The slide 5
`
`depiction of an Examiner’s Office Action rejection in view of the ’910 publication
`
`reflects an incomplete record. FRE106. Slide 29 presents only a portion of Fig. 23.
`
`Petitioner fails to mention that the Office Action challenges were overcome during
`
`prosecution or that the ’910 publication specifically identifies the 30mol% cationic
`
`lipid concentration as the best concentration and that all subsequent in vivo testing
`
`was limited to formulations having 30% or less cationic lipid. EX1015 ¶¶335, 337-
`
`354; see also Surreply, 15-16; EX2043, 12:18-20, 16:6-11, 17:24-19:24.
`
`
`
`-1-
`
`
`
`
`
`2.
`Slides 6, 7, 53, 55
`These slides are more prejudicial than probative as they falsely represent the
`
`1:57 as one single formulation. FRE403. EX1001, 3:45-56 (defining the “1:57
`
`formulation” as those including “a cationic lipid comprising from about 52 mol %
`
`to about 62 mol % of the total lipid present in the particle”); see also POR, 33-37
`
`(detailing the ’069 patent’s testing of multiple 1:57 formulations); EX2008.
`
`3.
`Slides 10 and 11
`It was Petitioner’s witness, Dr. Janoff – not Patent Owner – that testified for
`
`limiting the claimed invention to SNALPs. EX2001, 118:19-119:4, 119:9-17,
`
`120:5-6, 121:14-25. In the ’739 IPR, the Board confused Dr. Janoff’s interpretation
`
`with the more tempered construction advanced by Patent Owner. Slides 10 and 11
`
`are thus irrelevant and more prejudicial than probative. FRE401, 403
`
`4.
`Slide 14
`Slide 14 is an incomplete representation of the cited evidence, and is more
`
`prejudicial than probative. FRE401, 403. Dr. Janoff’s initially proffered definition
`
`in his ’739 IPR declaration (referenced in Slide 14) was rejected at institution in
`
`the ’739 IPR and abandoned by Petitioner. During cross-examination, Dr. Janoff
`
`repeatedly testified that the claimed particle of the ’739 IPR should be defined as a
`
`SNALP. EX2001, 118:19-119:4, 119:9-17, 120:5-6, 121:14-25; see also POR, 10.
`
`
`
`-2-
`
`
`
`
`
`5.
`Slide 21
`To the extent Petitioner relies on slide 21 as supporting a phospholipid range
`
`of 5 mol % to about 90 mol %, it is irrelevant to the challenge advanced in the
`
`petition materials. FRE401. Petitioner never presented such an invalidity theory in
`
`the petition. Rather, the petition alleged that one might arrive at phospholipid
`
`ranges of 0-19.5% and 0-19% after making a series of assumptions. Pet. 39, 54.
`
`Indeed, paragraph [0152] of the ’189 publication as shown on slide 21 was never
`
`relied upon in the petition.
`
`6.
`Slides 22, 24, 26
`These slides are irrelevant to the instituted grounds and are more prejudicial
`
`than probative. FRE401, FRE 403. The petition never argued that the 2:40
`
`formulation was a starting point for optimization. Tellingly, slides 22, 24, and 26
`
`do not offer any citations to the petition and instead only point to the reply, where
`
`such arguments were first introduced.
`
`7.
`Slide 27
`The content of this slide is irrelevant to establishing prima facie obviousness
`
`– the ’069 patent is not prior art against itself. FRE401. Thus, to the extent that
`
`any relevance is attributed to slide 27, it supports the criticality of the claimed
`
`range and the validity of the ’069 patent.
`
`
`
`-3-
`
`
`
`
`
`8.
`Slide 28
`Slide 28 is irrelevant to the obvious inquiry in the manner submitted.
`
`FRE401. WO2010088537 is not a reference for any of the instituted grounds.
`
`Indeed, it is not prior art to the ’069 patent at all. To the extent that the reference is
`
`relied upon, it demonstrates post-filing data reflecting criticality of the claimed
`
`range. See also POR, 37-43; Surreply, 3.
`
`9.
`Slide 30
`Slide 30 is a yet another new, attorney-generated graphical representation of
`
`unsubstantiated argument of a fabricated “trend.” Petitioner’s own witness, Dr.
`
`Anchordoquy, conceded that there were “hundreds, if not thousands” publications
`
`existing before the time of invention – none of which are identified on slide 30.
`
`EX2043, 29:25-30:4, 30:25-31:7; Surreply, 15. Further, Petitioner plots for the
`
`time on slide 30 an additional datapoint for the year 2008, presumably based on the
`
`’069 patent itself. Slide 30 is thus an incomplete and prejudicial depiction of the
`
`state of the art and, as a further extension of new arguments asserted in reply, has
`
`no relevance to the invalidity theories presented in the petition. FRE106, 401, 403.
`
`10.
` Slide 31
`The new assertion of a “trend” to “keep PEG low” was never presented in
`
`the petition or in any of Petitioner’s briefings. Slide 31 is thus irrelevant to the
`
`obviousness theories advanced in the petition materials. FRE401. Slide 31
`
`mischaracterizes the very evidence it cites, rendering slide 31 more prejudicial than
`-4-
`
`
`
`
`
`
`
`probative. FRE403. Paragraph 98 as depicted in slide 31 cites to EX1024, which
`
`describes conjugated lipids at 10% concentrations – far higher than the ranges
`
`claimed in the ’069 patent. EX1024, 22 (citing Judge, EX2042, 335).
`
`11. Slide 32
`Slide 32 is an incomplete document as it omits Dr. Thompson’s extensive
`
`testimony and corroborating evidence that higher PEG concentrations (e.g., 5-
`
`10%) were typical. EX2031, ¶¶48-49; EX1025, 57:1-7, 62:3-6, 132:9-133:23,
`
`175:3-13; FRE106.
`
`12. Slide 33
`Slide 33 is irrelevant to the instituted grounds, as Petitioner has never argued
`
`that there is a trend for including non-cationic lipids. FRE401. To the contrary,
`
`Petitioner cited submitted numerous references, each at most describing non-
`
`cationic lipids (e.g. phospholipids or cholesterol) as non-required, optional
`
`components. EX1005, ¶¶12, 120 (conjugated lipid optional), ¶¶97-115 (cholesterol
`
`optional), ¶92 (neutral lipid is optionally a phospholipid); EX1004, ¶150
`
`(conjugated lipid optional), ¶152 (cholesterol optional), ¶79 (non-cationic lipid is
`
`optionally a phospholipid); see also Surreply, 14.
`
`13. Slide 34
`Slide 34 is irrelevant as an argument that was never advanced in the petition
`
`materials and lacks supporting evidence. FRE401. Petitioner has failed to present
`
`
`
`-5-
`
`
`
`
`
`any meaningful discussion or evidence regarding an “accepted cholesterol range”
`
`or any motivation for using the range identified on slide 34.
`
`14. Slide 35
`Presenting new arguments, slide 35 is irrelevant and more prejudicial than
`
`probative. FRE106, FRE403. The petition materials never argued that there is an
`
`“accepted phospholipid range.” Indeed, slide 35 reflects Petitioner’s ever evolving
`
`position on the purported phosphide range taught by the prior art. Surreply, 9-20.
`
`The petition argued making a series of assumptions to arrive at phospholipid
`
`ranges of 0-19.5 mol% and 0-19 mol%. Pet. 39, 54. The reply changed tack,
`
`conflated non-cationic lipids with phospholipids and advanced a range of 5-90
`
`mol%. Reply, 5. Now, for the first time in this proceeding, slide 35 alleges a
`
`phospholipid range of 0-70 mol%.
`
`15. Slide 37
`The newly annotated figures from Lin and Ahmad are erroneous and
`
`incomplete documents, and prejudicial as they mischaracterize the results reported
`
`in those references. FRE106, FRE403. In contrast, both references describe
`
`transfection efficiency plateauing below 50 mol%. EX1006, 3315; EX1007, 740.
`
`Further, slide 37 omits the more probative evidence of Petitioner’s own witness,
`
`Dr. Janoff, testifying that the overall goal of Lin and Ahmad was to reduce the
`
`concentration of cationic lipid in formulations. EX2002, 31:7-39:9; see also
`
`
`
`-6-
`
`
`
`
`
`EX2006, 409:3-19 (“the bottom line message of Lin and Ahmad is how to reduce
`
`cationic lipid concentration in a formulation...”), 251:3-22, 252:11-19.
`
`16. Slide 38
`The quotations on slide 38 are incomplete writings and prejudicial. FRE106,
`
`FRE403. Far more probative are the relevant passages from the ’069 patent
`
`expressly distinguishing lipoplexes from lipid particles of the invention. EX1001,
`
`2:8-9 (“Cationic liposome complexes are large, poorly defined systems that are not
`
`suited for systemic applications”); see also EX2001, 122:1-24 (Dr. Janoff
`
`testifying that lipoplex particles were fundamentally different than those described
`
`in the current specification, and outside the scope of the patent); Surreply, 6.
`
`17. Slide 44
`Slide 44 advances yet another new argument seeking to locate a
`
`phospholipid range, including a new argument that a phospholipid of 0-65 mol%
`
`was taught by the ’554 publication, making the slide irrelevant and more
`
`prejudicial than probative. FRE401, FRE403; see Objections to Slide 35.
`
`18. Slides 47, 48 & 49
`Slides 47, 48, and 49 are irrelevant, lacking in underlying basis, and are an
`
`incomplete writing. FRE106, FRE401, FRE403. These slides omit the ’069
`
`patent’s disclosure that “the 1:57 SNALP formulation … was the most potent at
`
`reducing ApoB expression in vivo” EX1001, 72:21-24. Further, with respect to the
`
`error bars, the conclusions drawn on the slides are prejudicial. Dr. Janoff testified
`-7-
`
`
`
`
`
`
`
`that his conclusions were based solely on a visual inspect. EX2033, 113:2-8,
`
`122:12-123:23 (“Q. That's based on a visual inspection of the figure? A. That's the
`
`only thing available to me here.”). Yet, he made clear that he had problems with
`
`his vision. EX2001, 19-25 (“I have difficulty with my eyesight in general now”);
`
`see also EX2033, 7:19-8:3. More probative is his testimony that “I have no reason
`
`not to believe the data.” EX2033, 104:8-9.
`
`Petitioner also mischaracterizes the reported data on these slides. For
`
`instance, Petitioner fails to disclose on slide 47 that groups 2, 4, 5, and 7 are also
`
`2:40 formulations that were clearly outperformed by the 1:57 formulation of group
`
`11. See e.g., EX1001, Table 4, Fig. 2.
`
`19. Slide 52
`Slide 52 depicts Dr. Thompson’s testimony regarding the data presented in
`
`the ’069 patent itself. Thus, it is irrelevant to the obvious attack advanced in that it
`
`is not reflective of a person of ordinary skill in the art’s understanding prior to the
`
`invention. FRE401. Further, the quoted passage is incomplete. FRE106. Dr.
`
`Thompson’s testimony made clear that cationic lipids were understood to be toxic
`
`when administered in vivo. EX2006, 244:6-9 (“It's because the cationic lipid is
`
`toxic … It doesn't matter whether it's protonatable or not. It's still toxic.”). Even
`
`Petitioner’s own publications provide extensive discussion about the toxicity
`
`
`
`-8-
`
`
`
`
`
`concerns of ionizable cationic lipids, including DLinDMA. EX2037, 21:10-12;
`
`EX2031, ¶86; see also POR, 29-30.
`
`20. Slide 56
`Slide 56 presents incomplete testimony and is more prejudicial than
`
`probative. FRE106, FRE403. Petitioner omits Dr. Thompson’s testimony regarding
`
`a difference in the perspective of a person of ordinary skill before and after the
`
`invention’s disclosure. EX2006, 405:5-12 (“Q. Would the perspective of a person
`
`of ordinary skill in the art prior to the `435 patent be the same as someone in the
`
`field having studied the experimental data presented in the `435 patent? … [A.]
`
`The individual or the experimentalist after the `435 patent would benefit from that
`
`new knowledge.”). Petitioner’s arguments of unpredictability undermine any
`
`belated assertions of routine optimization.
`
`21. Slide 57
`Slide 57 is an incomplete document and mischaracterizes Dr. Thompson’s
`
`testimony with respect to Figure 2. FRE106, FRE403. Dr. Thompson explained
`
`that “Figure 2 is an experiment that is holding ratios of conjugate lipid and cationic
`
`lipid constant across a family of cationic lipids for a direct comparison,
`
`performance comparison, at keeping of though every -- all variables but cationic
`
`lipid type constant.” EX2006, 412:11-15. Thus, the conclusion presented on slide
`
`
`
`-9-
`
`
`
`
`
`57 misrepresents witness testimony, is more prejudicial than probative, and lacks
`
`underlying basis.
`
`22. Slides 61
`The conclusory assertions on slide 61 lack underlying basis such as any
`
`supporting calculations. FRE705. Slide 51 is also an incomplete representation of
`
`the record and conflicts with the testimony of Petitioner’s own witness. E.g.
`
`EX2003, ¶33 (Dr. Janoff explaining that “[Patisiran] … contains 50% cationic
`
`lipid, 38.5% cholesterol, 10% DSPC and 1.5% PEG”). Further, Petitioner omits
`
`Dr. Anchordoquy’s testimony that, even under his calculations, the formulations
`
`would produce a population of particles infringing the claims of the ’069 patent.
`
`EX2043, 72:24-73:3 (“Q. … with a 50 percent cationic lipid formulation, plus or
`
`minus 5 percent variability would give you a range of 45 percent to 55 percent
`
`cationic lipid; right? A. Sure”). The conclusions of slide 61 are thus irrelevant to
`
`the invalidity arguments presented in the petition, and are more prejudicial than
`
`probabtive. Indeed, Petitioner was well-aware of Patent Owner’s arguments with
`
`respect to commercial success and chose not to address any of those arguments or
`
`supporting evidence in the petition. POPR, 1-2, 10-11; POR, 31 n.4. Accordingly,
`
`such arguments are untimely and overly prejudicial.
`
`
`
`
`
`-10-
`
`
`
`
`
`Dated: April 20, 2020
`
`
`
`
`
`Respectfully submitted,
`/ Michael T. Rosato /
`Michael T. Rosato, Lead Counsel
`Reg. No. 52,182
`
`
`
`
`
`-11-
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`This is to certify that I caused to be served a true and correct copy of the
`
`foregoing Patent Owner’s Notice of Objection to Demonstrative Exhibits was
`
`served on April 20, 2020, on the Petitioner at the correspondence address of the
`
`Petitioner as follows:
`
`Michael Fleming
`C. Maclain Wells
`IRELL & MANELLA LLP
`mfleming@irell.com
`mwells@irell.com
`ModernaIPR@irell.com
`
`
`
`
`
`
`
`
`
`Dated: April 20, 2020
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Michael T. Rosato /
`Michael T. Rosato, Lead Counsel
`Reg. No. 52,182
`
`
`
`-12-
`
`